Red light therapy for thyroid health targets the autoimmune damage that drives Hashimoto's thyroiditis, the most common cause of hypothyroidism worldwide. For the roughly 7.5% of adults living with Hashimoto's globally (Hu et al., 2022), standard treatment has not changed in decades: levothyroxine every morning, for life. The medication replaces what the damaged thyroid can no longer produce. It does not stop the damage. A 2026 systematic review (Berisha-Muharremi & Humolli), the first to formally evaluate light therapy for Hashimoto's, pooled six clinical studies. It found consistent reductions in thyroid antibodies, improved hormone measures, and lower medication needs. Clinicians call the treatment photobiomodulation. The evidence is early, consistent, and worth examining.
Key Takeaways
- A 2026 systematic review, the only formal systematic review of photobiomodulation for Hashimoto's thyroiditis, pooled six human clinical studies from 2010 to 2025 and found consistent reductions in thyroid antibodies, improved hormone measures, and lower levothyroxine doses across the evidence base. All protocols used near-infrared wavelengths in the 820-850 nm range. (Berisha-Muharremi & Humolli, 2026)
- In the field's foundational placebo-controlled trial (Höfling et al., 2012), treated patients needed less than half the thyroid medication of the placebo group (38.59 µg/day versus 106.88 µg/day), with significantly lower thyroid antibodies and improved gland appearance on ultrasound. A six-year follow-up (Höfling et al., 2018) confirmed the benefit held with no safety concerns.
- Red light therapy for Hashimoto's is best understood as a complementary approach used alongside medical care. Studies remain relatively small, several pair light with supplements, and no multi-center trial has tested a standardized protocol. The consistency across independent research teams and a six-year safety record are genuine strengths; larger unified trials are the next step.
What Hashimoto's Thyroiditis Is, and Why Standard Treatment Leaves a Gap
Hashimoto's thyroiditis is an autoimmune disease in which the immune system attacks the thyroid gland, gradually destroying its ability to produce hormones. It causes up to 85% of hypothyroidism cases in regions with adequate iodine, affecting women at four to ten times the rate of men (Chaker & Papaleontiou, 2025). The damage extends beyond hormones: a meta-analysis of over 36,000 participants found more than three times the odds of depression and more than twice the odds of anxiety in people with autoimmune thyroiditis (Siegmann et al., 2018).
Levothyroxine replaces the hormones the gland can no longer make, and for most patients it restores normal blood chemistry. The autoimmune process, the ongoing inflammation, and the structural damage to the gland continue unchecked (Berisha-Muharremi & Humolli, 2026). A systematic review of 30 studies found that most reported persistent symptoms or lower quality of life even in patients whose labs were normal (Groenewegen et al., 2021). That gap between normal lab values and persistent symptoms is where photobiomodulation research sits.
How Red Light Therapy Targets Thyroid Health: Seven Biological Mechanisms
Red and near-infrared light in the 630-850 nm range passes through the skin of the neck and reaches the thyroid, which sits just beneath the surface. Inside the cells, the light is absorbed by a protein within the structures that produce energy. That absorption triggers a chain of biological responses that map directly onto the biology of Hashimoto's. CuraYou's guide to how red light therapy works at the cellular level covers the underlying biology in depth (Wong-Riley et al., 2005).
One principle governs all of these effects: the dose matters in both directions. More light is not automatically better. Low-to-moderate light stimulates cells; too much can shut the same processes down (Huang et al., 2009; Hamblin, 2018).
1. Restoring Cellular Energy in Damaged Thyroid Tissue
Evidence tier: foundational cell study; direct human-brain measurement; thyroid-specific animal study
Thyroid cells are among the most energy-hungry in the body. When the autoimmune attack damages their internal energy-producing structures, hormone output and self-repair both decline. A foundational neuron study established that 670 nm and 830 nm light restored energy production after metabolic toxins had shut it down. The most effective wavelengths matched the absorption pattern of the key enzyme involved, confirming it as the primary light-absorbing target (Wong-Riley et al., 2005). That energy effect has since been measured in living people: brain imaging showed a significant increase in energy production after a single 670 nm session in healthy older adults (Fear et al., 2023). In the thyroid specifically, near-infrared light restored thyroid cell function after radiation damage in an animal model, recovering hormone-related outputs toward normal (Yoo et al., 2021). The 2026 systematic review identified this energy restoration as a foundational mechanism behind the clinical improvements seen across trials.
2. Reducing the Autoimmune Antibody Attack
Evidence tier: pilot study; randomized controlled trial; large cohort study; 12-month controlled trial
Thyroid antibodies (listed as anti-TPO and anti-TG on lab work) mark the gland for immune destruction. Reducing them is a direct sign that an intervention is slowing the disease. Across the clinical evidence, photobiomodulation consistently lowers these antibodies. In the Höfling et al. (2010) pilot, anti-TPO fell approximately 41%. The placebo-controlled trial (Höfling et al., 2012) confirmed lower levels in the treated group versus placebo. In a study of 350 Hashimoto's patients (Erçetin et al., 2020), the light-treated group showed a greater reduction than the supplement-only group. And the 12-month trial (Berisha-Muharremi et al., 2025) confirmed reductions in both antibody types at one year. Every study that measured antibodies pointed the same direction.
3. Lowering Oxidative Stress in Thyroid Tissue
Evidence tier: sham-controlled randomized trial; human RCT corroboration
Making thyroid hormone requires hydrogen peroxide, which means the gland generates damaging molecules as part of its normal function. Adding the chronic inflammation of Hashimoto's on top creates a tissue environment under constant oxidative assault. A trial comparing active treatment against a convincing placebo (Tunç et al., 2024) measured this directly in 46 Hashimoto's patients. At three months, the active group showed measurably improved oxidative-stress markers, including higher levels of the body's primary built-in antioxidant, compared with sham. In a tissue where hydrogen peroxide is part of normal function, restoring that antioxidant capacity means restoring the cells' ability to survive their own biology. Broader human evidence supports the pattern: a randomized trial in elite athletes (Tomazoni et al., 2019) found that light therapy raised antioxidant activity and lowered oxidative-damage markers.
4. Improving Blood Flow to the Thyroid Gland
Evidence tier: randomized placebo-controlled ultrasound study; randomized controlled blood-flow trial
Good blood supply delivers oxygen to thyroid cells and clears away the waste of the inflammatory process. Using color Doppler ultrasound, a placebo-controlled study (Höfling et al., 2012) measured thyroid blood flow before and after treatment and found increased flow in the treated group versus placebo. The mechanism runs through nitric oxide: near-infrared light releases nitric oxide stored inside cells, relaxing blood vessel walls. A randomized trial (Gavish et al., 2020) captured the size of this effect. Near-infrared light raised blood flow by 27% immediately, climbing to 54% over the twenty minutes afterward. For a gland under autoimmune siege, better circulation means more oxygen, better clearance of inflammatory debris, and a healthier environment for the cells that remain.
5. Shifting the Inflammatory Immune Response
Evidence tier: direct thyroid measurement; comprehensive immunomodulation review
Hashimoto's is driven by a pro-inflammatory, tissue-destroying branch of the immune system. Shifting that balance away from destruction is central to slowing the disease. Direct thyroid evidence exists: Höfling et al. (2014) measured a key anti-inflammatory, tolerance-promoting signal in autoimmune thyroiditis patients and found it rose after treatment. A 2025 immunomodulation review (Al Balah et al.) confirmed that photobiomodulation shifts immune cells toward tolerance and repair rather than destruction, in a wavelength- and dose-dependent manner. The 2026 systematic review identified this immune shift as a central mechanism: reduced pro-inflammatory signaling and increased immune tolerance, preventing ongoing autoimmune destruction of thyroid tissue. For a wider discussion, see CuraYou's guide to red light therapy for inflammation.
6. Improving the Structure of the Gland
Evidence tier: pilot study with ultrasound; six-year follow-up; 12-month controlled trial
On ultrasound, a healthy thyroid appears bright and uniform. As Hashimoto's progresses, the gland grows darker and patchier as immune cells infiltrate and tissue is destroyed. In the 2010 pilot (Höfling et al.), computerized analysis of ultrasound images showed the treated tissue looked more like healthy thyroid afterward. The six-year follow-up (Höfling et al., 2018) found that a higher share of the treated group maintained normal thyroid size. The most detailed structural data comes from the 12-month trial (Berisha-Muharremi et al., 2025): in 98 women, the light-plus-supplements group achieved greater thyroid volume normalization than supplements alone. Better ultrasound appearance tracks with less immune infiltration and suggests the tissue is recovering, consistent with broader evidence that photobiomodulation supports cell renewal (de Freitas & Hamblin, 2016).
7. Addressing Persistent Symptoms: Fatigue, Sleep, and Quality of Life
Evidence tier: sham-controlled randomized trial; additional controlled studies
For many people with Hashimoto's, the hardest part is the symptoms that persist even after hormone levels are corrected: crushing fatigue, poor sleep, daytime sleepiness, anxiety, and low mood. Sixty Hashimoto's patients were randomized to active or sham treatment in the Tunç et al. (2026) trial. At three months, the active group improved across all measured symptoms: fatigue severity, sleep quality, daytime sleepiness, anxiety, and mood, compared with sham (registered as ClinicalTrials.gov NCT06735040). The earlier Tunç et al. (2024) trial had already shown quality-of-life gains alongside the oxidative stress reductions, and the Erçetin et al. (2020) cohort of 350 patients reported improved quality of life as well.
Conclusion
Hashimoto's thyroiditis is an autoimmune disease that produces a hormone shortage as its consequence. For decades, the only available treatment has addressed the shortage while leaving the cause untouched. Levothyroxine replaces what the thyroid can no longer make; it does not protect the gland from the autoimmune process destroying it.
Red and near-infrared light therapy acts on seven mechanisms studied in Hashimoto's: cellular energy, the antibody attack, oxidative stress, blood flow, inflammatory immune signaling, gland structure, and the persistent symptoms that levothyroxine leaves behind. The evidence is not equal across all seven. Antibody reduction has the most consistent clinical support; cellular energy has the most established mechanism; symptom improvement has the strongest sham-controlled design. Structural improvement and blood flow changes have direct thyroid measurement but smaller samples.
The clinical evidence, now gathered in a 2026 review of six studies, consistently shows lower medication needs, lower antibodies, better gland structure, less oxidative stress, and improved quality of life (Berisha-Muharremi & Humolli, 2026). A placebo-controlled trial showed treated patients needing less than half the medication of the placebo group, with a six-year follow-up confirming the benefit held safely (Höfling et al., 2012; Höfling et al., 2018). By the standards of pharmaceutical development, this evidence is early. By the standards of what it offers people managing Hashimoto's whose usual treatment has not been enough, it is worth taking seriously.
Most of my Hashimoto's patients are frustrated because their labs look normal but they still feel exhausted. The levothyroxine is doing its job on the hormone side. But the autoimmune process, the inflammation, the oxidative damage to the gland: those keep running underneath. That is exactly the gap this research is trying to close. The consistency of the results across independent teams is what makes it worth watching.— Dr. William Carter, MD
